Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02629861 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine
A Phase 3 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 875
- Enrollment target
NCT02629861 is a Phase 3 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 875 participants.
The verdict
NCT02629861, a Phase 3 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 875 participants
- Enrollment target
Study Summary
The study is being conducted to evaluate two doses of TEV-48125 in adult patients with episodic migraine
Interventions
- DRUG Placebo
- DRUG Fremanezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 875 participants |
| Start Date | 2016-03-23 |
| Est. Completion | 2017-04-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02629861
The ClinicalTrials.gov registry entry for NCT02629861 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 875 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02629861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02629861 about?
NCT02629861 is a clinical study titled "Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine". The study is being conducted to evaluate two doses of TEV-48125 in adult patients with episodic migraine
What is the current status of trial NCT02629861?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 875 participants. The study started on 2016-03-23. Estimated completion is 2017-04-10.
What interventions are being tested in trial NCT02629861?
The interventions under investigation include: Placebo (DRUG), Fremanezumab (DRUG).
Who is sponsoring clinical trial NCT02629861?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.